英国高血压成人晚间与晨间服用常规降压药的心血管结局(TIME研究):前瞻性、随机、开放标签、盲法终点临床试验
TIME研究为英国前瞻性、实用性、去中心化、平行组研究,纳入≥18岁高血压且至少服用一种降压药的成人,1:1随机分配至晨间(0600-1000时)或晚间(2000-0000时)服用全部常规降压药。主要终点为血管性死亡或非致死性心肌梗死或非致死性卒中住院的复合终点。共随机分配21104例(晚间组10503例,晨间组10601例),中位随访5.2年,主要终点事件晚间组362例(3.4%,0.69事件/100患者年)vs晨间组390例(3.7%,0.72事件/100患者年),未调整HR 0.95(95%CI 0.83-1.10;p=0.53)。作者认为晚间服药与晨间服药在主要心血管结局上无差异,患者可按方便时间服药。
要点
- 晚间服用常规降压药与晨间服用相比,主要心血管复合终点未调整HR 0.95(95%CI 0.83-1.10;p=0.53),无统计学显著差异。
- 晚间组主要终点事件362例(3.4%,0.69事件/100患者年)vs晨间组390例(3.7%,0.72事件/100患者年)。
- 中位随访5.2年(IQR 4.9-5.7),共21104例高血压成人随机分配,晚间组10503例、晨间组10601例。
- 作者认为患者可按方便且能减少不良效应的时间服用常规降压药。
- 未发现安全性问题。
适用人群与场景
- 英国≥18岁高血压成人,且至少服用一种降压药;共21104例随机分配(晚间组10503例,晨间组10601例)。
- 平均年龄65.1岁(SD 9.3);12136例(57.5%)为男性,8968例(42.5%)为女性;19101例(90.5%)为白人,98例(0.5%)为黑人、非洲人、加勒比人或英国黑人(1637例[7.8%]未报告种族);2725例(13.0%)有既往心血管疾病。
处置流程与药物剂量
- 将全部常规降压药在晨间(0600-1000时)或晚间(2000-0000时)服用,随机1:1分配,无限制、分层或最小化。
研究设计与关键结果
- 研究设计:前瞻性、实用性、去中心化、平行组研究,在英国进行;2011年12月17日至2018年6月5日筛查24610例,随机分配21104例至晚间组(n=10503)或晨间组(n=10601)。
- 主要终点:血管性死亡或非致死性心肌梗死或非致死性卒中住院的复合终点,至首次发生事件时间,意向性治疗人群分析。
- 主要终点结果:晚间组362例(3.4%)发生事件(0.69事件[95%CI 0.62-0.76]/100患者年),晨间组390例(3.7%)发生事件(0.72事件[95%CI 0.65-0.79]/100患者年;未调整HR 0.95[95%CI 0.83-1.10];p=0.53)。
- 随访:截至2021年3月31日,中位随访5.2年(IQR 4.9-5.7);晚间组529/10503例(5.0%)和晨间组318/10601例(3.0%)退出所有随访。
- 安全性:未发现安全性问题。
证据类型、等级与局限
- 证据类型:前瞻性、随机、开放标签、盲法终点临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为晚间服用常规降压药与晨间服用在主要心血管结局上无差异。
- 作者建议患者可按方便且能减少不良效应的时间服用常规降压药。
指南或共识出处
- TIME研究,发表于Lancet,注册号EudraCT 2011-001968-21和ISRCTN 18157641;资助:英国心脏基金会(British Heart Foundation)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Studies have suggested that evening dosing with antihypertensive therapy might have better outcomes than morning dosing. The Treatment in Morning versus Evening (TIME) study aimed to investigate whether evening dosing of usual antihypertensive medication improves major cardiovascular outcomes compared with morning dosing in patients with hypertension.
METHODS: The TIME study is a prospective, pragmatic, decentralised, parallel-group study in the UK, that recruited adults (aged ≥18 years) with hypertension and taking at least one antihypertensive medication. Eligible participants were randomly assigned (1:1), without restriction, stratification, or minimisation, to take all of their usual antihypertensive medications in either the morning (0600-1000 h) or in the evening (2000-0000 h). Participants were followed up for the composite primary endpoint of vascular death or hospitalisation for non-fatal myocardial infarction or non-fatal stroke. Endpoints were identified by participant report or record linkage to National Health Service datasets and were adjudicated by a committee masked to treatment allocation. The primary endpoint was assessed as the time to first occurrence of an event in the intention-to-treat population (ie, all participants randomly assigned to a treatment group). Safety was assessed in all participants who submitted at least one follow-up questionnaire. The study is registered with EudraCT (2011-001968-21) and ISRCTN (18157641), and is now complete.
FINDINGS: Between Dec 17, 2011, and June 5, 2018, 24 610 individuals were screened and 21 104 were randomly assigned to evening (n=10 503) or morning (n=10 601) dosing groups. Mean age at study entry was 65·1 years (SD 9·3); 12 136 (57·5%) participants were men; 8968 (42·5%) were women; 19 101 (90·5%) were White; 98 (0·5%) were Black, African, Caribbean, or Black British (ethnicity was not reported by 1637 [7·8%] participants); and 2725 (13·0%) had a previous cardiovascular disease. By the end of study follow-up (March 31, 2021), median follow-up was 5·2 years (IQR 4·9-5·7), and 529 (5·0%) of 10 503 participants assigned to evening treatment and 318 (3·0%) of 10 601 assigned to morning treatment had withdrawn from all follow-up. A primary endpoint event occurred in 362 (3·4%) participants assigned to evening treatment (0·69 events [95% CI 0·62-0·76] per 100 patient-years) and 390 (3·7%) assigned to morning treatment (0·72 events [95% CI 0·65-0·79] per 100 patient-years; unadjusted hazard ratio 0·95 [95% CI 0·83-1·10]; p=0·53). No safety concerns were identified.
INTERPRETATION: Evening dosing of usual antihypertensive medication was not different from morning dosing in terms of major cardiovascular outcomes. Patients can be advised that they can take their regular antihypertensive medications at a convenient time that minimises any undesirable effects.
FUNDING: British Heart Foundation.
参考来源
- Mackenzie IS, Rogers A, Poulter NR, et al. Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial. Lancet. 2022. PMID: 36240838. doi:10.1016/S0140-6736(22)01786-X
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。